Loading clinical trials...

A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir | Clinical Trials | Clareo Health

COMPLETEDPHASE4

A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir

A Prospective Multicenter Observational Study for Characterization of Renal Function G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir

NCT03144635•Kyushu University

View on ClinicalTrials.gov

Summary

The regimen using grazoprevir plus elbasvir treatment is promising in Japan, because it may safely be used for the elderly patients with renal dysfunction. Grazoprevir and elbasvir are metabolized in the liver and do not require dose-adjustment for patients with renal dysfunction. However, no data related to efficacy and safety of the grazoprevir plus elbasvir treatment for Japanese elderly patients with renal dysfunction (eGFR\<60 mL/min/1.73m2) have been reported. Therefore, physicians are at a loss whether or not to treat the patients with renal dysfunction due to no evidence. The aim of this study is to investigate the improvement of serum endostatin level of Japanese patients with CKD stage 3 after grazoprevir (NS3/4A protease inhibitor) plus elbasvir (NS5A replication complex inhibitor) treatment by a prospective, multicenter cohort study.

Eligibility

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Subjects aged 20 years or older.
•2. Patients positive for HCV RNA for over 6 months and infected with genotype 1b chronic hepatitis C, including compensated cirrhosis.
•3. Patients without co-infection of hepatitis B virus.
•4. Patients without co-infection of human immunodeficiency virus
•5. Patients with moderate chronic kidney disease (CKD stage 3) (eGFR: 30-59 mL/min/1.73m2). A diagnosis of CKD is only confirmed if repeated eGFR tests for at least 90 days.

Exclusion Criteria

•1. Patients with decompensated cirrhosis (Child Pugh B and C)
•2. Patients with albumin \<3.0 g/dL and platelets \<75,000 /μL
•3. Patients with autoimmune hepatitis
•4. Constant heavy alcohol drinkers (converted to ethanol ≥60 g/day)
•5. Patients who have a history of hypersensitivity to grazoprevir and elbasvir
•6. Patients who are pregnant females, or females who may become pregnant, or females who are breastfeeding
•7. Patients with heart disease that is hard to control (e.g., very recent cardiac infarction, severe heart failure, unstable arrhythmia)
•8. Patients who are under medication with drugs listed as contraindication in a package insert of grazoprevir plus elbasvir treatment
•9. Patients judged (by the physician in charge of research) to be inappropriate as subjects for the study for any other reasons.

Locations (1)

Kyushu University Hospital

Fukuoka, Japan

Key Dates

Start Date

April 1, 2017

Primary Completion Date

December 31, 2017

Completion Date

September 20, 2018

Last Updated

June 3, 2019

Enrollment

ACTUAL participants

Conditions

Hepatitis C ViralChronic Kidney Disease stage3

Interventions

Grazoprevir plus Elbasvir

DRUG

A Pragmatic Approach to CKD Patient Education

NCT05138419

Chronic Kidney Disease stage3Chronic Kidney Disease stage4+2 more

View study

COMPLETEDNA

PR-0164 First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion System

NCT06037265

Chronic Kidney Disease stage3Chronic Kidney Disease stage4+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 3, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir

Inclusion Criteria

Exclusion Criteria

A Pragmatic Approach to CKD Patient Education

PR-0164 First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion System

Effects of Brazil Nut Supplementation in Patients With Chronic Kidney Disease Undergoing Conservative Treatment

Study of Sulphoraphane in Chronic Kidney Disease

Validation and Evaluation of a Newly Developed Mobile Diet App

Living With CKD: An E-Learning Platform for Adolescents With CKD About the Disease and Its Management